Secreted and transmembrane polypeptides and nucleic acids encoding the same
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
1 - 57 . (canceled)
58 . A diagnostic method, the method comprising assaying a biological sample from a mammalian subject for amplification of a gene encoding a PRO381 polypeptide having the amino acid sequence of SEQ ID NO: 145 and comparing the level of nucleic acid encoding the PRO381 polypeptide in said sample to the level of said nucleic acid in a normal biological sample wherein gene amplification is indicative that the sample contains cancerous cells.
59 . The method of claim 58 wherein said sample is a tissue sample.
60 . The method of claim 59 wherein said tissue sample is from lung or colon cancer.
61 . The method of claim 60 wherein said amplification is detected by a polymerase chain reaction (PCR)-based assay.
62 . The method of claim 61 wherein said PCR-based assay is TAQMAN™ PCR.
63 . The method of claim 61 wherein said PCR-based assay uses, as a probe, an isolated nucleic acid molecule of at least 20 nucleotides capable of hybridizing under stringent conditions to:
(a) the nucleic acid sequence of SEQ ID NO: 144 or a complement thereof;
(b) the full-length coding sequence of the cDNA deposited under ATCC accession number 209927 or a complement thereof;
wherein, said stringent conditions use 50% formamide, 5×SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC and 50% formamide at 55° C., followed by a wash comprising of 0.1×SSC containing EDTA at 55° C., wherein said isolated nucleic acid molecule is suitable for use as a PCR primer or probe.
64 . The method of claim 63 wherein the isolated nucleic acid molecule is at least 50 nucleotides.
65 . The method of claim 63 wherein the isolated nucleic acid molecule is at least 60 nucleotides.
66 . The method of claim 63 wherein the isolated nucleic acid molecule is at least 70 nucleotides.
67 . The method of claim 63 wherein the isolated nucleic acid molecule is at least 80 nucleotides.
68 . The method of claim 63 wherein the isolated nucleic acid molecule is at least 90 nucleotides.
69 . The method of claim 63 wherein the isolated nucleic acid molecule is at least 100 nucleotides.
70 . A method for diagnosing lung or colon cancer, the method comprising assaying a tissue sample from a mammalian subject for amplification of a gene encoding a PRO381 polypeptide having the amino acid sequence of SEQ ID NO: 145 and comparing the level of nucleic acid encoding the PRO381 polypeptide in said sample to the level of nucleic acid in a normal tissue sample, and diagnosing said subject with cancer if amplification of said gene is detected.
71 . A method for detecting overexpression of polypeptide of SEQ ID NO: 145, the method comprising assaying a tissue sample from a mammalian subject for expression of a polypeptide having the amino acid sequence of SEQ ID NO: 145 and comparing the level of expression in said sample to the level of expression in a normal tissue sample wherein overexpression of polypeptide of SEQ ID NO: 145 is indicative that the sample is derived from cancerous tissue.
72 . The method of claim 71 wherein said sample is from lung or colon cancer.
73 . The method of claim 71 wherein overexpression is detected with an antibody that specifically binds to the PRO381 polypeptide of SEQ ID NO:145.
74 . The method of claim 73 wherein said antibody is a monoclonal antibody.
75 . The method of claim 73 wherein said antibody is a humanized antibody.
76 . The method of claim 73 wherein said antibody is an antibody fragment.
77 . The method of claim 73 wherein said antibody is labeled.